Days of PEX, in the ICU, in the hospital, and plasma volume during the treatment2In the HERCULES study, CABLIVI* reduced volume and duration of PEX and time spent in hospital vs PEX and immunosuppression alone2 *In conjunction with PEX and immunosuppression. ICU=intensive care unit. References CABLIVI. Summary of Product Characteristics (SmPC). Sanofi. Scully M, Cataland SR, Peyvandi F, et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi:10.1056/NEJMoa1806311 Peyvandi F, Cataland S, Scully M, et al. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021;5(8):2137-2141. doi:10.1182/bloodadvances.2020001834 Assessment report: CABLIVI. European Medicines Agency. Accessed April 3, 2024. https://www.ema.europa.eu/en/documents/variation-report/cablivi-h-c-4426-ii-0021- epar-assessment-report-variation_en.pdf CABLIVI. Prescribing information. Genzyme Corporation. → Cablivi API
